Fig. 6From: SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanomaSEMA6A expression predicts low efficacy of dabrafenib+trametinib in BRAF-mut melanoma patients. A: Progression-free Survival (PFS) and B: Overall Survival (OS) in patients with high and low SEMA6A from the cohort RECI2Back to article page